Navigation Links
Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
Date:9/14/2007

READING, Pa., Sept. 14 /PRNewswire-FirstCall/ -- Arrow International, Inc. (Nasdaq: ARRO) today reported that Proxy Governance, Inc. a leading independent proxy voting advisory firm, has advised its clients to vote to approve Arrow's planned $45.50 merger with Teleflex Incorporated (NYSE: TFX) and for the re-election of Arrow's current Board of Directors at the Annual Meeting of Arrow shareholders on September 20, 2007.

Proxy Governance is the fourth proxy advisory firm to recommend a vote for the merger agreement. On September 7, as previously reported, Glass, Lewis & Co. recommended that Arrow shareholders vote to approve the merger agreement with Teleflex and for the election of all of the Arrow director nominees. On September 12, Egan Jones also recommended its clients support the merger and the re-election of the full Arrow Board of Directors and Institutional Shareholders Services (ISS) recommended its clients approve the merger and support the election of a majority of the current Board of Directors.

R. James Macaleer, Chairman commented, "We are pleased with the universal support for the Teleflex merger that we have received from four leading proxy advisory firms. We are also pleased that Glass Lewis, Proxy Governance, and Egan Jones also support the re-election of the full Board of Directors. However, we think that ISS is introducing unnecessary uncertainty into the voting process by recommending that shareholders support two McNeil Trust nominees and withhold votes from five McNeil Trust nominees. We believe that any change in the composition of the Board at this point could be detrimental to the timely completion of the Teleflex merger. We strongly believe that shareholders will benefit by voting for all of Arrow's director nominees. This Board is fully committed to completing the Teleflex transaction and acting in the best interests of all shareholders."

Arrow shareholders are reminded to vote the WHITE proxy card today to support the merger agreement with Teleflex and the election of the full slate of Arrow director nominees who will manage any events which may arise following the Annual Meeting and prior to the consummation of the merger. Arrow shareholders are cautioned NOT to return a blue proxy to the McNeil Trust.

All votes are important. For shares held by a brokerage firm or bank, Arrow shareholders should provide them with instructions on how to vote or they will be unable to vote on certain issues, including the adoption of the merger agreement. Please return the WHITE proxy card to the broker or bank to ensure that shares are voted or vote by telephone or Internet.

Shareholders with questions regarding the solicitation may contact Arrow International's proxy solicitor, Morrow & Co., Inc. toll-free at 1-800-662-5200.

About Arrow

Arrow develops, manufactures and markets a broad range of clinically advanced, disposable catheters and related products for critical and cardiac care. The company's products are used primarily by anesthesiologists, critical care specialists, surgeons, emergency and trauma physicians, cardiologists, interventional radiologists and other healthcare providers. Arrow's news releases and other company information can be found on the World Wide Web at http://www.arrowintl.com. Arrow's common stock trades on the NASDAQ Global Select Market(TM) under the symbol ARRO.

Additional Information

In connection with the proposed acquisition of Arrow by Teleflex Incorporated and Arrow's 2007 Annual Meeting of Shareholders, Arrow filed a definitive proxy statement with the SEC, on August 24, 2007 and will be filing other documents with the SEC. Arrow has furnished a definitive proxy statement to its shareholders, together with a WHITE proxy card. Arrow shareholders are strongly advised to carefully read Arrow's definitive proxy statement. Shareholders may obtain the definitive proxy statement on file with the SEC and any other documents filed by Arrow with the SEC for free at the internet website maintained by the SEC at http://www.sec.gov. Shareholders may obtain free copies of the definitive proxy statement and any amendments and supplements to the definitive proxy statement at Arrow's website at http://www.arrowintl.com or by writing to Arrow International, Inc., 2400 Bernville Road, Reading, Pennsylvania 19605. In addition, copies of Arrow's proxy materials may be requested by contacting our proxy solicitor, Morrow & Co. at (800) 662-5200 toll-free or by writing to Morrow & Co., 470 West Avenue, Stamford, CT 06902. Arrow and its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Additional information regarding the names, affiliations and interests of individuals who are participants in the solicitation of proxies of Arrow's shareholders is available in Arrow's definitive proxy statement filed with the SEC on August 24, 2007.


'/>"/>
SOURCE Arrow International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Delhi Government To Interlink All Major Hospitals Through e-Governance
2. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
3. Rat joins list of cloned animals
4. Richard Gere Joins Indian Stars For Fight Against AIDS
5. Enbrel Joins with Methotrexate to Cure Rheumatoid Arthritis
6. Anoushka Joins Hands With WFP to Feed the Poor
7. India Joins Hands With Global Body for Vaccine Research
8. Another Statewide Organization Joins the Fight Against Assisted Suicide
9. Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius
10. Short Glasses Make You Drink More
11. Over indulgence more so when intake is in short glasses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... ... provides insurance and financial consultation services to residents in the Sacramento/Folsom region, is ... Another Chance treatment facility. , The Another Choice Another Chance treatment center in ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 ... ... A new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... dogs. The study was published in the prestigious Journal of Veterinary Science & ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... service based in Dallas, Texas, is condemning "scam operations" carried out by unethical ... to bring these scam operations to a halt. According to Texas Premier Locksmith, ...
(Date:12/7/2016)... , ... December 07, 2016 ... ... announced its newest portable bioelectronic medicine device WellnessPro Plus for consumers and ... substantially enhances the WellnessPro platform by expanding the treatment modalities available in ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows readers ... follows. , “Fred Rides a Train” is the creation of published author, Janet ... her teen years in Michigan. The "Fred, the Dog" series is her first attempt ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016   Rx Savings Solutions ... and its Public Employees Insurance Agency (PEIA) to ... to their innovative healthcare software, ultimately saving money on their ... and provide its members with access to our software that ... more effective, affordable therapy can be found," says Michael ...
(Date:12/7/2016)... , Dec. 7, 2016  Varian Medical Systems ... to its previously announced plans to separate its Imaging ... via a tax-free distribution to Varian stockholders of common ... company that will hold the Imaging Components business.  As ... be executed by the end of January 2017, Varian ...
(Date:12/7/2016)... 7,2016  Based on its recent analysis ... & Sullivan recognizes Nemaura Pharma Limited with ... for Enabling Technology Leadership. Nemaura Pharma,s transdermal ... traditional drug delivery technologies, especially in delivering ... delivery technologies, Memspatch and Micropatch respectively, facilitate ...
Breaking Medicine Technology: